Generate Biomedicines, Inc.

NASDAQ:GENB

Asset Management

Financial Services
$10.38 +0.91%

+$0.13 today

Market cap
$1.34B
Beta
0.19
P/E (TTM)
-3.5
EPS (TTM)
-$4.06
52W Low $11.00High $16.75

Volume 1.05M

Average 0.55M

GENB Debt Repayment

Cash used to repay borrowings during the period.

Generate Biomedicines, Inc.NASDAQ: GENB

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment of -$1.12M in Q1 FY2026

Q1 FY2026 debt repayment was -$1.12M.

Context

  • Debt repayment amounted to 25.6% of revenue in FY2025, down 28.8 pp from a year earlier.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.12M— QoQ
Last fiscal yearDec 2025
-$8.16M-26.6% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-26.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
(8.16M) USD
Year-over-year change
+26.6%

Debt Repayment vs competitors

How GENB compares with its peers on the latest reported figures

  • GENB's FY2025 debt repayment of $8.16M is the 3rd largest of the 5 companies compared; the peer median is $8.86M.
  • Its year-over-year change of -26.6% is the 3rd highest of 4, against a peer median of -25.0%.
  • Debt repayment amounts to 25.6% of revenue for GENB, versus a peer median of 90.6%.
GENB Competitors Peer median
Debt Repayment for GENB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INBXInhibrx Biosciences, Inc.LTM Mar 2026$74.99M -25.0%—5768.6%
ABCLAbCellera Biologics Inc.LTM Sep 2026$17.72M -29.4%—26.1%
GENBGenerate Biomedicines, Inc.FY2025$8.16M -26.6%—25.6%
ABSIAbsci CorporationLTM Mar 2026$2.85M -20.2%—155.1%
STROSutro Biopharma, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding GENB) $8.86M-25.0%—90.6%

Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD

Generate Biomedicines, Inc.

NASDAQ:GENB

Intrinsic Alpha fair value

Locked

Current Price

$10.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.